Embark Biotech
-
Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal
Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
Share/ Aug 30, 2023 at 6:46 PM
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
MedCity >> Inbox
Get the latest industry news first when you subscribe to our newsletter.
We will never sell or share your information without your consent. See our privacy policy.Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.